NCT01702129View on ClinicalTrials.gov

Anti-EGFR Immunoliposomes in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Solid Tumors
Interventions
DRUG

anti-EGFR immunoliposomes loaded with doxorubicin

All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks

Trial Locations (1)

4031

University Hospital, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT01702129 - Anti-EGFR Immunoliposomes in Solid Tumors | Biotech Hunter | Biotech Hunter